Weekly FDA Drug Pipeline Calendar (Nov 14 - Nov 19)
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
$Moderna (MRNA.US)$'s new Covid booster triggered a stronger immune response against omicron BA.5 and also appears to work against the emerging BQ.1.1 subvariant, according to the company.
The U.S. Covid public health emergency will remain in place past Jan. 11 after the federal government did not notify states or health-care provides on Friday of any intent to lift the declaration.
$Merrimack Pharmaceuticals (MACK.US)$ and Ipsen announced that its Phase 3 NAPOLI 3 trial of Onivyde to treat metastatic pancreatic ductal adenocarcinoma (mPDAC) met its primary endpoint. Merrimack is eligible for up to a $450 million milestone payment for the cancer treatment. Shares closed the week up 215% at $12.28.
$Athersys (ATHX.US)$ priced a $5.5 million public offering of 5,004,545 shares of common stock and warrants. Shares closed the week down 74% at $0.65.
$Clovis Oncology (CLVS.US)$ warned of a possible bankruptcy amid liquidity concerns in its quarterly earnings report. This quarter it reported a net losses of $187.5 million. Shares closed the week down 70% at $0.29.
$Adaptimmune Therapeutics (ADAP.US)$ reported data from its Phase 1 trial SURPASS evaluating ADP-A2M4CD8 to treat solid tumors. Adaptimmune reported an objective response rate (ORR) increased to 52% from 44%. Shares closed the week up 55% at $2.51.
Source: CNBC, BioPharmCatalyst, Benzinga
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
We are the content provider of Moomoo Courses.
913Followers
8Following
1481Visitors
Follow
72987343 : is this pro big pharma dr fauci he should know he helped create the disease killing virus ask him
versatile Auroch_864 : Can I have my investment status?